Phaseline

Targets › PNLIP

PNLIP (Pancreatic triacylglycerol lipase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Aug 2027.

Plays an important role in fat metabolism. It preferentially splits the esters of long-chain fatty acids at positions 1 and 3, producing mainly 2-monoacylglycerol and free fatty acids, and shows considerably higher activity against insoluble emulsified substrates than against soluble ones. (UniProt, P16233)

Open in Phaseline: the race on PNLIP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Texas Southwestern Medical CenterOrlistat
Gastric lipase inhibitor; Pancreatic lipase inhibitor
LIPF, PNLIPPhase 2Type 1 HyperlipoprotenemiaAug 2027

Conditions

Type 1 Hyperlipoprotenemia (1)

Modalities

small molecule (1)

Companies

University of Texas Southwestern Medical Center (1)

Related targets

LIPF (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.